Mani Keshtgarpour

Suggest Changes
Learn More
BACKGROUND Only 15% of patients with non-small cell lung cancer (NSCLC) treated with oral epidermal growth factor tyrosine kinase inhibitor gefitinib, as a second-line therapy have objective(More)
  • 1